Annexon Biosciences
Annexon Biosciences raises $125M Series D at $750M valuation
Quick Facts
Annexon Biosciences: Series D Funding Round
Annexon Biosciences has successfully raised $125M in Series D funding, reaching a valuation of $750M.
Company Overview
Classical complement pathway inhibitors
Funding Details
The Series D round was led by GV, with participation from Alta Partners, Omega Funds, Cowen Healthcare Investments, Redmile Group.
Company Information
- Headquarters: 180 Kimball Way, South San Francisco, CA 94080
- Founded: 2011
- Employees: 150+
- Category: Biotech
Investment
Annexon Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- GV: Verified investor in Series D
- Alta Partners: Verified investor in Series D
- Omega Funds: Verified investor in Series D
- Cowen Healthcare Investments: Verified investor in Series D
- Redmile Group: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...